Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Key Takeaways Zepbound helped patients lose 50 pounds, compared to 33 pounds with WegovyThe study showed Zepbound users lost ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

For the first time, a study in The New England Journal of Medicine is comparing the most popular drugs for weight loss, ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

In addition, nearly 32% of people taking Zepbound lost at least a quarter of their body weight, compared to about 16% of those taking Wegovy, the study found. Weight loss was about 6% lower in men ...